JLE

European Journal of Dermatology

MENU

Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas Volume 33, numéro 5, September-October 2023

Figure 1.

 Forest plots of treatment success in terms of obtaining IGA 0/1 for pimecrolimus vs vehicle in children (A) and mixed populations (B).

RR >1.0 favours pimecrolimus. CI: confidence interval; IGA: Investigator’s Global Assessment; RR: risk ratio; wk: week.

Figure 2.

Forest plots of treatment success in terms of obtaining IGA 0/1 for pimecrolimus vs tacrolimus 0.03% in children.

RR >1.0 favours pimecrolimus. CI: confidence interval; IGA: Investigator’s Global Assessment; RR: risk ratio; wk: week.

Figure 3.

Forest plot of treatment success in terms of obtaining facial IGA 0/1 for pimecrolimus vs vehicle in children (sensitive skin area).

RR >1.0 favours pimecrolimus. CI: confidence interval; IGA: Investigator’s Global Assessment; RR: risk ratio; wk: week.